<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290781</url>
  </required_header>
  <id_info>
    <org_study_id>SHP647-303</org_study_id>
    <secondary_id>2017-000573-37</secondary_id>
    <nct_id>NCT03290781</nct_id>
  </id_info>
  <brief_title>Study of the Effect of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies</brief_title>
  <acronym>FIGARO UC 303</acronym>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of SHP647 as maintenance therapy in
      participants with moderate to severe ulcerative colitis (UC) who achieved clinical response
      in induction studies. This is a phase 3, randomized, double-blind, placebo-controlled,
      parallel-group efficacy and safety study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">September 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Remission is defined as a composite score of patient reported symptoms using daily e-diary and centrally read endoscopy as follows: stool frequency subscore of 0 or 1 with at least a 1-point change from induction baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from induction study baseline in stool frequency subscore, and rectal bleeding subscore of 0,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of subjects with sustained remission, ie, in remission at the SHP647-303 Week 52 visit, among subjects who were in remission at the time of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response Based on Composite Score at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical response (composite) is defined as a decrease from induction study baseline in the composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (&gt;=) 1 point or a subscore for rectal bleeding less than or equal to (&lt;=) 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mucosal Healing Based on Endoscopic and Histologic Assessment, at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of &lt;=2. The Geboes Score will be used to evaluate histologic remission and to complement the endoscopic subscore in the assessment of mucosal healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Glucocorticoid-free Clinical Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Glucocorticoid-free clinical remission is defined as clinical remission in addition to not requiring any treatment with glucocorticoids for at least 4 weeks prior to the Week 52 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Glucocorticoid-free Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Glucocorticoid-free remission is defined as remission in addition to not requiring any treatment with glucocorticoids for at least 4 weeks prior to the Week 52 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to Week 68</time_frame>
    <description>Treatment-emergent AEs (TEAEs) are defined as AEs with start dates at the time of or following the first exposure to investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to Week 68</time_frame>
    <description>Clinical laboratory assessments include serum chemistry, hematology and urinalysis. The investigator will assess out-of-range clinical laboratory values for clinical significance, to indicate whether or not the values are clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Findings in Physical Examinations Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to Week 68</time_frame>
    <description>Complete physical examinations will be carried out which include review of the following body systems: general appearance, skin, head, eyes, ears, nose, and throat (HEENT), heart, lungs, confrontational visual fields (eyes), breast (optional), abdomen, external genitalia (optional), extremities, neurologic function, back, and lymph nodes. Any changes from the baseline in physical examination findings that are deemed clinically significant in the opinion of the investigator are to be recorded as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to Week 68</time_frame>
    <description>Vital sign assessments include blood pressure, pulse, respiratory rate, and temperature. Any deviations from baseline that are deemed clinically significant in the opinion of the investigator are to be recorded as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to Week 68</time_frame>
    <description>12-lead ECG will be recorded and a central ECG reader will be used in the study. Any abnormality in ECG assessed by an investigator considered as clinically significant will be reported as AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Develop Antidrug Antibodies to SHP647</measure>
    <time_frame>Week 12 up to Week 52</time_frame>
    <description>Serum samples will be analysed for presence of antidrug antibodies to SHP647. Participants who showed positive results for SHP647 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Remission Based on Total Mayo Score at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Remission is determined by Mayo score of &lt;=2 with no individual subscore exceeding 1, at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response Based on Total Mayo Score at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical response based on total mayo score is defined as a decrease from induction study baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Remission Based on Partial Mayo Score Over Time</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Partial Mayo score consists of the Mayo score without the endoscopic subscores and ranges from 0 to 9 points. Percentage of participants having partial Mayo score of &lt;=2 with no individual subscore greater than (&gt;) 1 over time will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Remission Over Time</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Percentage of participants with clinical remission over time with both rectal bleeding and stool frequency subscores of 0 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Remission at Week 52 With Endoscopic Subscore of 0</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with endoscopic remission, as defined by centrally read endoscopic subscore 0 at week 52 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Deep Remission at the Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants in deep remission at week 52 ie, Deep remission is defined as an endoscopic and rectal bleeding subscore of 0, stool frequency &lt;=1 and a Geboes score of &lt;=2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Endoscopic Remission Based on Centrally Read Endoscopic Subscore</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with sustained endoscopic remission ie, in endoscopic remission at the Week 52 visit among participants who were in remission at the time of baseline, as defined by a centrally read endoscopic subscore of 0 or 1 (modified, excludes friability) will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Mucosal Healing at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with sustained mucosal healing at week 52. Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of &lt;=2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Sustained Deep Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants in sustained deep remission at week 52 ie, deep remission at week 52 visit among participants who were in remission at the time of baseline will be reported. Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore &lt;=1 and a centrally read Geboes score of &lt;=2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Sustained Clinical Remission Over Time</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Percentage of participants in sustained clinical remission over time ie, clinical remission at baseline and each visit, as defined by stool frequency subscore of 0 or 1 with at least a 1-point change from induction study baseline in stool frequency subscore, and rectal bleeding subscore of 0 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Sustained Endoscopic Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants in sustained endoscopic remission at week 52 ie, endoscopic remission at Week 52 visit among participants who were in remission at the time of baseline, with a Mayo endoscopic subscore of 0 will be reported. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Remission Based on Total Mayo Score</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of Participants with sustained remission at week 52 ie, remission at Week 52 visit among participants who were in remission at the time of baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Clinical Remission Over Time</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Percentage of participants with sustained clinical remission over time (ie, clinical remission at baseline and each visit) with both rectal bleeding and stool frequency subscores of 0 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Glucocorticoid-free Clinical Remission Over Time</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Among subjects in Glucocorticoids at study start, the percentage of participants in glucocorticoid-free clinica remission assessed every 4 weeks. Glucocorticoid-free clinical remission is defined as clinical remission in addition to not requiring any treatment with glucocorticoids in subjects who previously received glucocorticoids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Induction Study Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>IBDQ is a psychometrically validated patient-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better health-related quality of life (HRQL). A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Induction Study Baseline in Short Form-36 Health Survey (SF-36), version 2, acute (physical and mental component summary scores and individual domain scores)</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalizations and Total Inpatient Days</measure>
    <time_frame>Week 68</time_frame>
    <description>Incidence of hospitalizations and total inpatient days during the entire study period were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in Abdominal Pain Based on Participant e-Diary</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>Change from induction study baseline in abdominal pain based on participant daily e-diary entries will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in Urgency Based on Participant e-Diary</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>Change from induction study baseline in urgency item scores based on participant daily e-diary entries will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in Diarrhea Based on Participant e-Diary</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>Change from induction study baseline in diarrhea based on participant daily e-diary entries will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in absolute stool frequency Based on Participant e-Diary</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>Change from induction study baseline in absolute stool frequency based on participant daily e-diary entries will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in absolute rectal bleeding Based on Participant e-Diary</measure>
    <time_frame>Week 12 up Week 52</time_frame>
    <description>Change from induction study baseline in absolute rectal based on participant daily e-diary entries will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Induction Study Baseline in total sign/symptom score based on participant daily e-diary entries (sum of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) will be reported.</measure>
    <time_frame>Week 12 up to Week 52</time_frame>
    <description>Change from induction study baseline in total sign/symptom score based on participant daily e-diary entries (sum of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">772</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>SHP647 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 25 milligram (mg) of SHP647 or placebo and achieved a clinical response in one of the induction studies (SHP647-301 or SHP647-302) will receive 25 mg of SHP647 as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP647 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 75 mg of SHP647 or placebo and achieved a clinical response in one of the induction studies (SHP647-301 or SHP647-302) will receive 75 mg of SHP647 as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received 25 mg or 75 mg SHP647 or placebo matched to SHP647 in the induction studies (SHP647-301 or SHP647-302) will receive placebo matched to SHP647 as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP647</intervention_name>
    <description>1 milliliter (mL) of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide an intended dose of drug (25 or 75 mg).</description>
    <arm_group_label>SHP647 25 mg</arm_group_label>
    <arm_group_label>SHP647 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 mL of sterile aqueous buffered solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following inclusion criteria to be eligible for
        enrollment into the study.

          -  Participants and/or their parent or legally authorized representative must have an
             understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          -  Participants must be able to voluntarily provide written, signed, and dated
             (personally or via a legally authorized representative) informed consent and/or
             assent, as applicable, to participate in the study.

          -  Participants must have completed the 12-week induction treatment period.

          -  Participants must have achieved clinical response in induction study. Clinical
             response is defined as:

               1. A decrease from the induction study baseline in the composite score of
                  patient-reported symptoms using daily e-diary and centrally read endoscopy of at
                  least 2 points and at least 30 percent (%), with an accompanying decrease in the
                  subscore for rectal bleeding greater than or equal to (&gt;=)1 point or a subscore
                  for rectal bleeding less than or equal to (&lt;=) 1 OR

               2. A decrease from the induction study baseline in total Mayo score of at least 3
                  points and at least 30%, with an accompanying decrease in the rectal bleeding
                  subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.

        For eligibility assessment, clinical response will be determined based on the centrally
        read endoscopy performed during screening and at Week 12 of induction study.

          -  Participants receiving any treatment(s) for ulcerative colitis (UC) are eligible
             provided they have been, and are anticipated to be, on a stable dose for the
             designated period of time.

          -  Participants are males or nonpregnant, nonlactating females who, if sexually active,
             agree to comply with the contraceptive requirements of the protocol, or females of
             nonchildbearing potential. Males and females of reproductive potential who are
             sexually active must agree to use acceptable contraception for the duration of the
             study.

        Exclusion Criteria:

        Participants are excluded from the study if any of the following exclusion criteria are
        met:

          -  Participants who had major protocol deviation(s) (as determined by the sponsor) in
             induction study.

          -  Participants who permanently discontinued investigational product because of an
             adverse event (AE), regardless of relatedness to investigational product, in induction
             study.

          -  Participants who are likely to require surgery for UC during the study period.

          -  Participants are females who became pregnant during induction study, females who are
             planning to become pregnant during the study period, or males or females of
             childbearing potential not agreeing to continue acceptable contraception methods
             through the conclusion of study participation.

          -  Male participants who are planning to donate sperm must agree not to do so for the
             duration of the study and through 16 weeks after last dose of investigational product.

          -  Participants who, in the opinion of the investigator or the sponsor, will be
             uncooperative or unable to comply with study procedures.

          -  Participants who have a newly diagnosed malignancy or recurrence of malignancy (other
             than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in
             situ of the uterine cervix that has been treated with no evidence of recurrence).

          -  Participants who have developed any major illness/condition or evidence of an unstable
             clinical condition (example [eg], renal, hepatic, hematologic, gastrointestinal
             (except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg,
             Felty's syndrome], or local active infection/infectious illness) that, in the
             investigator's judgment, will substantially increase the risk to the participant if he
             or she participates in the study.

          -  Participants with any other severe acute or chronic medical or psychiatric condition
             or laboratory or electrocardiogram (ECG) abnormality that may increase the risk
             associated with study participation or investigational product administration or may
             interfere with the interpretation of study results and, in the judgment of the
             investigator, would make the participant inappropriate for entry into this study.

          -  Participants with known exposure to Mycobacterium tuberculosis (TB) since testing at
             screening in induction study and who are without a generally accepted course of
             treatment.

          -  Participants who are investigational site staff members or relatives of those site
             staff members or participants who are sponsor employees directly involved in the
             conduct of the study.

          -  Participants who are participating in or plan to participate in other investigational
             studies (other than induction study) during study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Digestive Health</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chirag Trivedi</last_name>
      <phone>602-264-9100</phone>
      <email>ctrivedi@arizonadigestivehealth.com</email>
    </contact>
    <investigator>
      <last_name>Chirag Trivedi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Gottlieb</last_name>
      <phone>520-547-3020</phone>
      <email>ggottlieb@delsolresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gary Gottlieb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindred Medical Institute for Clinical Trials, LLC</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Mazen Jamal</last_name>
      <phone>951-220-4029</phone>
      <email>mazen.md@aol.com</email>
    </contact>
    <investigator>
      <last_name>M. Mazen Jamal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigid Boland</last_name>
      <phone>619-543-2347</phone>
      <email>bboland@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Brigid Boland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Lee</last_name>
      <phone>562-826-8000</phone>
      <email>robert.lee1a92a1@va.gov</email>
    </contact>
    <investigator>
      <last_name>Robert Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melvin Heyman</last_name>
      <phone>415-476-0820</phone>
      <email>mel.heyman@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Melvin Heyman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance Medical Research LLC</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vipin Gupta</last_name>
      <phone>954-428-2480</phone>
      <email>info@pioneerclinical.com</email>
    </contact>
    <investigator>
      <last_name>Vipin Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Kerman</last_name>
      <phone>305-243-2910</phone>
    </contact>
    <investigator>
      <last_name>David Kerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharma Research International Inc</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwabena Ayesu</last_name>
    </contact>
    <investigator>
      <last_name>Kwabena Ayesu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research - St. Petersburg</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venkata Iyunni, MD</last_name>
      <phone>727-546-1680</phone>
      <email>drnath@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Venkata Iyunni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Network</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Sarol</last_name>
      <phone>305-702-1594</phone>
    </contact>
    <investigator>
      <last_name>Juan Sarol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DBC Research</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Bender</last_name>
      <phone>954-537-2100</phone>
      <email>kbendermd@dbcresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Bender</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Specialists, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Salzberg</last_name>
      <phone>678-957-0057</phone>
      <email>bruceasalzberg@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Salzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Steinbook</last_name>
      <phone>706-321-0495</phone>
      <email>newtrials@serrg.com</email>
    </contact>
    <investigator>
      <last_name>Michael Steinbook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Hanauer</last_name>
      <phone>312-695-4929</phone>
      <email>shanauer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Hanauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Rubin</last_name>
      <phone>773-834-7414</phone>
      <email>drubin@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>David Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Association for Research and Education in Science - NAVREF</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marmy Shah</last_name>
      <phone>914-960-1653</phone>
      <email>marmy.shah@va.gov</email>
    </contact>
    <investigator>
      <last_name>Marmy Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dupage Medical Group</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Smith</last_name>
      <phone>630-833-0653</phone>
      <email>matthew.smith@dupagemd.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-State Gastroentrology Associates</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jones</last_name>
      <phone>859-594-4626</phone>
      <email>mjones-research@tsddc.com</email>
    </contact>
    <investigator>
      <last_name>Michael Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Hazard</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uday Shankar</last_name>
      <phone>606-439-3952</phone>
      <email>shankar.gastrohep@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Uday Shankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Hardi</last_name>
      <phone>301-652-5520</phone>
      <email>robert.hardi@capitaldigestivecare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Hardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri County Endoscopy</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anil Kankaria</last_name>
      <phone>301-373-7500</phone>
      <email>kan9600@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Kankaria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashwin Ananthakrishnan</last_name>
      <phone>617-724-3238</phone>
      <email>aananthakrishnan@partners.org</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ananthakrishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rohit Singhania</last_name>
      <phone>413-794-7364</phone>
      <email>rohit.singhaniamd@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Rohit Singhania</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Marie Houghton</last_name>
      <phone>774-442-4098</phone>
      <email>anne.foley@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Jean Marie Houghton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Higgins</last_name>
      <phone>734-764-0507</phone>
      <email>phiggins@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Van Norstrand</last_name>
      <phone>218-786-3985</phone>
    </contact>
    <investigator>
      <last_name>Michael Van Norstrand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Center PA</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfred McNair, Jr.</last_name>
      <phone>228-872-7612</phone>
      <email>lbrowndhc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alfred McNair, Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Biomedical Research Foundation - NAVREF</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarun Rai</last_name>
      <phone>816-861-4700</phone>
      <phone_ext>52475</phone_ext>
      <email>tarun.rai@va.gov</email>
    </contact>
    <investigator>
      <last_name>Tarun Rai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Ciorba</last_name>
      <phone>314-362-9039</phone>
      <email>mciorba@im.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Ciorba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Friedrich, Rubin, Panella, Sapienza, and Kaplounov, LLP</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth Rubin</last_name>
      <phone>201-569-7044</phone>
      <email>scopemd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seymour Katz</last_name>
      <phone>516-466-2340</phone>
      <email>seymour.katz@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Seymour Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen Scherl</last_name>
      <phone>212-746-5077</phone>
      <email>ejs2005@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Scherl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research Partners LLC</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franjo Vladic</last_name>
      <phone>440-953-1899</phone>
      <email>fvladic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Franjo Vladic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veteran's Research and Education Foundation - NAVREF</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohammad Madhoun</last_name>
      <phone>405-361-9482</phone>
      <email>mohammad-madhoun@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammad Madhoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Center For Digestive Health</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra El-Hachem</last_name>
      <phone>412-359-8900</phone>
      <email>sandra.elhachem@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Sandra El-Hachem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Research Foundation of Pittsburgh - NAVREF</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fadi Fouad Francis</last_name>
      <phone>412-360-3788</phone>
      <email>fadi.francis@va.gov</email>
    </contact>
    <investigator>
      <last_name>Fadi Fouad Francis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Beaulieu</last_name>
      <phone>615-322-4643</phone>
    </contact>
    <investigator>
      <last_name>Dawn Beaulieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Gastro</name>
      <address>
        <city>Union City</city>
        <state>Tennessee</state>
        <zip>38237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kofi Nuako</last_name>
      <email>md@conductclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Kofi Nuako</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kelsey Seybold Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Greg Galler</last_name>
      <phone>713-442-1223</phone>
      <email>greg.galler@kelsey-seybold.com</email>
    </contact>
    <investigator>
      <last_name>Greg Galler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manreet Kaur</last_name>
    </contact>
    <investigator>
      <last_name>Manreet Kaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manreet Kaur</last_name>
      <phone>713-798-6342</phone>
      <email>manreet.kaur@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Manreet Kaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research/Coastal Gastroenterology Associates, PA</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Advitya Malhotra</last_name>
      <phone>281-557-2527</phone>
    </contact>
    <investigator>
      <last_name>Advitya Malhotra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Val Hansen MD</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Val Hansen</last_name>
      <phone>801-797-9315</phone>
      <email>valhansen@live.com</email>
    </contact>
    <investigator>
      <last_name>Val Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Moses</last_name>
      <phone>802-847-8865</phone>
      <email>peter.moses@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Peter Moses</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Health Specialists</name>
      <address>
        <city>Galax</city>
        <state>Virginia</state>
        <zip>24333</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Benish</last_name>
      <phone>276-236-2947</phone>
      <email>rvbmd@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Robert Benish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Center at UWMC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Zisman</last_name>
      <phone>206-598-4377</phone>
      <email>tzisman@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Zisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Lee</last_name>
      <phone>206-598-4377</phone>
      <email>leesd@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Franciscan Digestive Care Associates</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Larson</last_name>
      <phone>253-272-8664</phone>
      <email>stevenlarson@fhshealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Kupec</last_name>
      <phone>304-293-4123</phone>
      <email>jkupec@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Kupec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio 9 de Julio SA</name>
      <address>
        <city>San Miguel De Tucumn</city>
        <state>Tucumn</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Fernndez</last_name>
      <phone>+543814301305</phone>
    </contact>
    <investigator>
      <last_name>Jorge Fernndez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>4710</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harald Hofer</last_name>
      <phone>+43072424152181</phone>
      <email>harald.hofer@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Harald Hofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine De Vos</last_name>
      <phone>+3293322371</phone>
      <email>martine.devos@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Martine De Vos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Banja Luka</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatjana Barac</last_name>
      <phone>+38751342574</phone>
      <email>barac.tatjana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tatjana Barac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Eurohospital</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Penka Akrabova</last_name>
      <phone>+359888</phone>
      <phone_ext>11</phone_ext>
      <email>akrabovap@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Penka Akrabova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Bitton</last_name>
      <phone>(514) 934-1934</phone>
      <email>alain.bitton@mchc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Alain Bitton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio</name>
      <address>
        <city>Bogot</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albis Hani de Ardila</last_name>
      <phone>+5712322118</phone>
      <email>albis.hani@javeriana.edu.co</email>
    </contact>
    <investigator>
      <last_name>Albis Hani de Ardila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servimed Empresa Unipersonal</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Plata Valdivieso</last_name>
      <phone>+5673163032851</phone>
    </contact>
    <investigator>
      <last_name>Jose Plata Valdivieso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacin Clnica Shaio</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reinaldo Rincon Sanchez</last_name>
      <phone>+3102619871</phone>
      <email>ramrs@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Reinaldo Rincon Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacin Cardioinfantil Instituto Cardiolgico</name>
      <address>
        <city>Bogot</city>
        <zip>110131</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Ceballos</last_name>
      <phone>+5716672727</phone>
    </contact>
    <investigator>
      <last_name>Jorge Ceballos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobn Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabin Juliao</last_name>
      <phone>+5744459753</phone>
    </contact>
    <investigator>
      <last_name>Fabin Juliao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Klinichki Bolnicki Centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marko Brinar</last_name>
    </contact>
    <investigator>
      <last_name>Marko Brinar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Karlovac</name>
      <address>
        <city>Karlovac</city>
        <state>Karlovacka upanija</state>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivana Kovacic</last_name>
    </contact>
    <investigator>
      <last_name>Ivana Kovacic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Borzan</last_name>
      <phone>+38531511511</phone>
    </contact>
    <investigator>
      <last_name>Vladimir Borzan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Virovitica</name>
      <address>
        <city>Virovitica</city>
        <zip>33000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matko Markotic</last_name>
    </contact>
    <investigator>
      <last_name>Matko Markotic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General County Hospital Vukovar</name>
      <address>
        <city>Vukovar</city>
        <zip>32000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Petrosevic</last_name>
    </contact>
    <investigator>
      <last_name>Ivan Petrosevic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Zadar</name>
      <address>
        <city>Zadar</city>
        <zip>23 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivo Klarin</last_name>
    </contact>
    <investigator>
      <last_name>Ivo Klarin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut klinicke a experimentalni mediciny</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavel Drastich</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Drastich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut klinicke a experimentalni mediciny</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavel Drastich</last_name>
      <phone>+420603869913</phone>
      <email>pavel.drastich@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Pavel Drastich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubickeho kraje, a.s. Orlickoustecka nemocnice</name>
      <address>
        <city>sti Nad Orlici</city>
        <zip>562 18</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Libor Gabalec</last_name>
    </contact>
    <investigator>
      <last_name>Libor Gabalec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Buisson</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Buisson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charit - Universittsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Baumgart</last_name>
      <phone>+4930450553277</phone>
      <email>daniel.baumgart@charite.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Baumgart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliches Universittsklinikum Bergmannsheil GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolff Schmiegel</last_name>
    </contact>
    <investigator>
      <last_name>Wolff Schmiegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universittsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Huber</last_name>
    </contact>
    <investigator>
      <last_name>Samuel Huber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitrios Christodoulou</last_name>
      <phone>+2651007611</phone>
      <email>dchristodoulou@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Christodoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Istvn Altorjay</last_name>
      <phone>+3652255196</phone>
      <email>altorjay@med.unideb.hu</email>
    </contact>
    <investigator>
      <last_name>Istvn Altorjay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glen Doherty</last_name>
      <phone>+35312214711</phone>
      <email>g.doherty@st-vincents.ie</email>
    </contact>
    <investigator>
      <last_name>Glen Doherty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigal Fishman</last_name>
      <phone>+97236974468</phone>
      <email>sigalf@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Sigal Fishman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Integrato Columbus</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Armuzzi</last_name>
      <phone>+39063503310</phone>
      <email>alearmuzzi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Armuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital at Yonsei University Health System - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Hee Cheon</last_name>
      <phone>+82222281990</phone>
      <email>geniushee@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jae Hee Cheon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Violeta Jakovlevaite</last_name>
      <phone>+370846396547</phone>
      <email>viletajak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Violeta Jakovlevaite</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Acelerada, S.C.</name>
      <address>
        <city>Distrito Federal</city>
        <zip>07020</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Bermudez Villegas</last_name>
      <phone>+525557813954</phone>
      <email>emiliobermudez14@yahoo.com.mx</email>
    </contact>
    <investigator>
      <last_name>Emilio Bermudez Villegas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <zip>2820</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geert D'Haens</last_name>
      <phone>+3215505011</phone>
      <email>g.dhaens@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Geert D'Haens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Ldz</city>
        <state>Ldzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elzbieta Czkwianianc</last_name>
      <phone>+48422711341</phone>
      <email>kpg@iczmp.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Elzbieta Czkwianianc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel Gonalves</last_name>
      <phone>+351253027000</phone>
      <email>mraquel.goncalves@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raquel Gonalves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiago Bana e Costa</last_name>
    </contact>
    <investigator>
      <last_name>Tiago Bana e Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cluj Clinical County Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Lucian Dumitrascu</last_name>
      <phone>+40722756475</phone>
      <email>dan_dumitrascu@yahoo.de</email>
    </contact>
    <investigator>
      <last_name>Dan Lucian Dumitrascu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Company Hepatolog, LLC</name>
      <address>
        <city>Samara</city>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Malova</last_name>
      <phone>+79033357481</phone>
      <email>alenamalova@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Malova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center ''Bezanijska Kosa''</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mirjana Cvetkovic</last_name>
      <phone>+381641608353</phone>
      <email>mikialeksa5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mirjana Cvetkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Zemun</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Predrag Dugalic</last_name>
    </contact>
    <investigator>
      <last_name>Predrag Dugalic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <state>umadijski Okrug</state>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natasa Zdravkovic-Petrovic</last_name>
    </contact>
    <investigator>
      <last_name>Natasa Zdravkovic-Petrovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou F. D. Roosevelta</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jozef Balaz</last_name>
      <phone>+421915071770</phone>
      <email>balaz@scouting.sk</email>
    </contact>
    <investigator>
      <last_name>Jozef Balaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus Barrio Andres</last_name>
      <phone>+34983420400</phone>
      <email>jbarrioa95@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Barrio Andres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Blach AG</name>
      <address>
        <city>Blach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51103</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Bhm</last_name>
      <phone>+492217712305</phone>
      <email>stephan.boehm@spitalbuelach.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Bhm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitt Zrich</name>
      <address>
        <city>Zrich</city>
        <state>Zrich (de)</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Biedermann</last_name>
      <phone>+41442551111</phone>
      <email>luc.biedermann@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Luc Biedermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyiv Municipal Clinical Hospital #18</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonid Bilianskyi</last_name>
      <phone>+380442346649</phone>
      <email>bls@ua.fm</email>
    </contact>
    <investigator>
      <last_name>Leonid Bilianskyi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <state>Shropshire</state>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffery Butterworth</last_name>
      <phone>+441743261000</phone>
      <email>jeff.butterworth@sath.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeffery Butterworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

